Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

“BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities. This relationship allows us to utilize our experience in iPSC process development to help advance potential cell therapies for cardiac diseases,” said Stefan Braam, CEO of Ncardia.

There are hundreds of millions of people worldwide that suffer from degenerative cardiovascular disease where the root cause is the loss of healthy heart muscle cells, and where medical treatment options are limited. BlueRock’s authentic cellular therapy is a novel approach that has the potential to transform the lives of patients, but will require the manufacture of our cell therapies at unprecedented scale. The Ncardia team has developed key technologies related to this scale-up challenge, and we are pleased to work with them as we advance BlueRock’s novel CELL+GENE platform towards the clinic and those patients in need.”

Emile Nuwaysir, President and CEO, BlueRock Therapeutics

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ncardia. (2020, January 23). Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes. News-Medical. Retrieved on February 21, 2020 from https://www.news-medical.net/news/20200123/Ncardia-and-Bluerock-Therapeutics-announce-collaboration-agreement-and-licensing-of-process-development-technologies-for-the-manufacture-of-iPSC-derived-cardiomyocytes.aspx.

  • MLA

    Ncardia. "Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes". News-Medical. 21 February 2020. <https://www.news-medical.net/news/20200123/Ncardia-and-Bluerock-Therapeutics-announce-collaboration-agreement-and-licensing-of-process-development-technologies-for-the-manufacture-of-iPSC-derived-cardiomyocytes.aspx>.

  • Chicago

    Ncardia. "Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes". News-Medical. https://www.news-medical.net/news/20200123/Ncardia-and-Bluerock-Therapeutics-announce-collaboration-agreement-and-licensing-of-process-development-technologies-for-the-manufacture-of-iPSC-derived-cardiomyocytes.aspx. (accessed February 21, 2020).

  • Harvard

    Ncardia. 2020. Ncardia and Bluerock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes. News-Medical, viewed 21 February 2020, https://www.news-medical.net/news/20200123/Ncardia-and-Bluerock-Therapeutics-announce-collaboration-agreement-and-licensing-of-process-development-technologies-for-the-manufacture-of-iPSC-derived-cardiomyocytes.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.